AI Article Synopsis

  • OAC switching, particularly from vitamin K antagonists (VKAs) to direct-acting OACs (DOACs), is frequent among atrial fibrillation (AF) patients, with dabigatran being the most common switch type prior to recent increases for apixaban.
  • There is conflicting evidence regarding the clinical outcomes and risks of stroke and bleeding associated with OAC switching, highlighting a need for more standardized definitions and reporting of switch outcomes.
  • Although adherence to medication remains stable, patients experience improved satisfaction with their therapy after switching OACs, and risk factors for stroke and bleeding are common reasons for switching.

Article Abstract

Introduction: Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF). Several factors may cause OAC switching.

Objectives: To examine the phenomenon of OAC switching in patients with AF, including all available evidence; frequency and patterns of switch, clinical outcomes, adherence, patient-reported outcomes, reasons for switch, factors associated with switch and evidence gaps.

Design: Scoping review.

Data Sources: MEDLINE, Embase and Web of Science, up to January 2022.

Results: Of the 116 included studies, 2/3 examined vitamin K antagonist (VKA) to direct-acting OAC (DOAC) switching. Overall, OAC switching was common and the definition of an OAC switch varied across. Switching from VKA to dabigatran was the most prevalent switch type, but VKA to apixaban has increased in recent years. Patients on DOAC switched more to warfarin than to other DOACs. OAC doses involved in the switches were hardly reported and patients were often censored after the first switch. Switching back to a previously taken OAC (frequently warfarin) occurred in 5%-21% of switchers.The risk of ischaemic stroke and gastrointestinal bleeding in VKA to DOAC switchers compared with non-switchers was conflicting, while there was no difference in the risk of other types of bleeding. The risk of ischaemic stroke in switchers from DOAC versus non-switchers was conflicting. Studies evaluating adherence found no significant changes in adherence after switching from VKA to DOAC, however, an increase in satisfaction with therapy were reported. Reasons for OAC switch, and factors associated with OAC switch were mostly risk factors for stroke and bleeding. Clinical outcomes, adherence and patient-reported outcomes were sparse for switches from DOACs.

Conclusions: OAC switching is common in patients with AF and patients often switch back to an OAC they have previously been on. There are aspects of OAC switching that have received little study, especially in switches from DOACs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151984PMC
http://dx.doi.org/10.1136/bmjopen-2023-071907DOI Listing

Publication Analysis

Top Keywords

oac switching
16
oac
12
oac switch
12
switching
9
switch
9
switching patients
8
patients atrial
8
atrial fibrillation
8
clinical outcomes
8
outcomes adherence
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!